CAS NO: | 195514-63-7 |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking theFKBPdomains. Rimiducid (AP1903) dimerizes theCaspase 9suicide switch and rapidly inducesapoptosis. | ||||||||||||||||
IC50& Target | EC50: 0.1 nM (FKBP, in HT1080 cells)[1] | ||||||||||||||||
体外研究 (In Vitro) | The human fibrosarcoma line HT1080 is engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human first apoptosis signal (Fas) intracellular domain. Rimiducid (AP1903) elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC50of ≈0.1 nM[1]. Maximal killing occurred in the presence of 3 to 10 nM Rimiducid (AP1903), and the IC50is approximately 0.2 nM. LV′VFas-transduced T lymphocytes expressing high levels of CD25 (top panel) are eliminated by with 66%±7.5% (n=10) efficiency. When cells are examined after CD25 expression returned to basal levels, 63%±4.7% (n=9) killing is observed after Rimiducid treatment[2]. | ||||||||||||||||
体内研究 (In Vivo) | Rimiducid (AP1903; i.v.,0.01, 0.1, 1, 10, and 100 mg/kg) elicits a dose-dependent decrease in serum human GH levels, with a half-maximal effective dose of 0.4±0.1 mg/kg[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 1411.63 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C78H98N4O20 | ||||||||||||||||
CAS 号 | 195514-63-7 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
*该产品在溶液状态不稳定,建议您现用现配,即刻使用。 | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(35.42 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |